因塞特医疗(INCY)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

INCY 因塞特医疗

盘前交易 04-03 07:07:22 EDT

62.33

+1.42

+2.33%

盘前59.51

-2.82-4.52%

04:39 EDT

最高62.53	最低60.27	成交量214.78万
今开60.90	昨收60.91	日振幅3.71%
总市值120.62亿	流通市值100.56亿	总股本1.94亿
成交额1.33亿	换手率1.33%	流通股本1.61亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"INCY","market":"US","secType":"STK","nameCN":"因塞特医疗","latestPrice":62.33,"timestamp":1743624000000,"preClose":60.91,"halted":0,"volume":2147752,"hourTrading":{"tag":"盘前","latestPrice":59.51,"preClose":62.33,"latestTime":"04:39 EDT","volume":8,"amount":488.789976,"timestamp":1743669560564},"delay":0,"floatShares":161331806,"shares":193524350,"eps":0.15,"marketStatus":"盘前交易","change":1.42,"latestTime":"04-03 07:07:22 EDT","open":60.9,"high":62.53,"low":60.27,"amount":133290827.169496,"amplitude":0.037104,"askPrice":69.47,"askSize":100,"bidPrice":58,"bidSize":4,"shortable":3,"etf":0,"ttmEps":0.15,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1743687000000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":62.33,"preHourTrading":{"tag":"盘前","latestPrice":59.51,"preClose":62.33,"latestTime":"04:39 EDT","volume":8,"amount":488.789976,"timestamp":1743669560564},"postHourTrading":{"tag":"盘后","latestPrice":60,"preClose":62.33,"latestTime":"19:57 EDT","volume":182566,"amount":11380769.4504,"timestamp":1743638222511},"volumeRatio":1.2662770539093906,"impliedVol":0.4864,"impliedVolPercentile":0.752},"requestUrl":"/m/hq/s/INCY/tweets","defaultTab":"tweets","newsList":[{"id":"2524447536","title":"因塞特4月2日成交额为1.33亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2524447536","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2524447536?lang=zh_cn&edition=full","pubTime":"2025-04-03 09:41","pubTimestamp":1743644502,"startTime":"0","endTime":"0","summary":"美东时间2025年4月2日，因塞特成交额为1.33亿美元，成交额较昨日减少15.12%，当日成交量为214.78万股。因塞特于2025年4月2日涨2.33%，报62.33美元，该股过去5个交易日涨1.75%，年初至今跌9.76%，过去60日跌10.48%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-04-02|1.33亿|-15.12%|214.78万|#|2025-04-01|1.57亿|52.91%|257.56万|#|2025-03-31|1.03亿|41.38%|170.34万|#|2025-03-28|7265.81万|-12.66%|119.86万|#|2025-03-27|8319.35万|-16.91%|137.10万|Incyte专注于小分子药物的发现与研发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250403094152a44bfaa2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4532","BK4588","INCY","BK4585","BK4550"],"gpt_icon":0},{"id":"2524189973","title":"因塞特3月31日成交额为1.03亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2524189973","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2524189973?lang=zh_cn&edition=full","pubTime":"2025-04-01 09:41","pubTimestamp":1743471706,"startTime":"0","endTime":"0","summary":"美东时间2025年3月31日，因塞特成交额为1.03亿美元，成交额较昨日增加41.38%，当日成交量为170.34万股。因塞特于2025年3月31日跌0.08%，报60.55美元，该股过去5个交易日跌3.55%，年初至今跌12.34%，过去60日跌12.34%。该公司首款皮肤科产品Opzelura于 2021 年获批用于治疗特应性皮炎，并于 2022 年获批用于治疗白癜风。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250401094153a6ab3d90&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4585","INCY","BK4588","BK4550","BK4532"],"gpt_icon":0},{"id":"2523596656","title":"因塞特3月28日成交额为7265.81万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2523596656","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2523596656?lang=zh_cn&edition=full","pubTime":"2025-03-29 09:38","pubTimestamp":1743212330,"startTime":"0","endTime":"0","summary":"美东时间2025年3月28日，因塞特成交额为7265.81万美元，成交额较昨日减少12.66%，当日成交量为119.86万股。因塞特于2025年3月28日跌0.13%，报60.6美元，该股过去5个交易日跌2.13%，年初至今跌12.26%，过去60日跌11.43%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-03-28|7265.81万|-12.66%|119.86万|#|2025-03-27|8319.35万|-16.91%|137.10万|#|2025-03-26|1.00亿|-37.99%|163.21万|#|2025-03-25|1.61亿|-2.11%|260.35万|#|2025-03-24|1.65亿|-38.39%|262.73万|Incyte专注于小分子药物的发现与研发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250329093854a6a81960&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4550","BK4532","BK4585","INCY","BK4139"],"gpt_icon":0},{"id":"2522260393","title":"因塞特3月26日成交额为1.00亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2522260393","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2522260393?lang=zh_cn&edition=full","pubTime":"2025-03-27 09:48","pubTimestamp":1743040134,"startTime":"0","endTime":"0","summary":"美东时间2025年3月26日，因塞特成交额为1.00亿美元，成交额较昨日减少37.99%，当日成交量为163.21万股。因塞特于2025年3月26日跌1.32%，报61.26美元，该股过去5个交易日涨1.52%，年初至今跌11.31%，过去60日跌11.93%。该公司首款皮肤科产品Opzelura于 2021 年获批用于治疗特应性皮炎，并于 2022 年获批用于治疗白癜风。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250327094859a6a57025&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","INCY","BK4585","BK4532","BK4139","BK4550"],"gpt_icon":0},{"id":"2520627082","title":"William Blair：下调Incyte评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2520627082","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2520627082?lang=zh_cn&edition=full","pubTime":"2025-03-18 19:59","pubTimestamp":1742299161,"startTime":"0","endTime":"0","summary":"William Blair：下调Incyte(INCY.US)评级，由优于大市调整至大市一致评级。因塞特(INCY.US)公司简介：因塞特医疗公司是一家生物制药公司，从事专利疗法的发现、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250318200519a69a91db&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INCY"],"gpt_icon":0},{"id":"2520624074","title":"William Blair：下调Incyte(INCY.US)评级，由优于大市调整至大市一致评级。","url":"https://stock-news.laohu8.com/highlight/detail?id=2520624074","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2520624074?lang=zh_cn&edition=full","pubTime":"2025-03-18 19:42","pubTimestamp":1742298168,"startTime":"0","endTime":"0","summary":"William Blair：下调Incyte(INCY.US)评级，由优于大市调整至大市一致评级。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/18194248839417.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["INCY"],"gpt_icon":0},{"id":"2518272264","title":"因塞特盘中异动 快速下跌5.02%报67.56美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518272264","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518272264?lang=zh_cn&edition=full","pubTime":"2025-03-12 00:58","pubTimestamp":1741712327,"startTime":"0","endTime":"0","summary":"北京时间2025年03月12日00时58分，因塞特股票出现异动，股价大幅跳水5.02%。截至发稿，该股报67.56美元/股，成交量65.9736万股，换手率0.34%，振幅5.65%。机构评级方面，在所有27家参与评级的机构中，41%的券商给予买入建议，56%的券商给予持有建议，3%的券商给予卖出建议。因塞特股票所在的生物技术行业中，整体跌幅为2.50%。该公司首款皮肤科产品Opzelura于 2021 年获批用于治疗特应性皮炎，并于 2022 年获批用于治疗白癜风。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250312005847a1d56828&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4139","BK4532","BK4588","BK4550","INCY"],"gpt_icon":0},{"id":"2516668460","title":"因塞特盘中异动 下午盘大幅跳水5.06%报69.78美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516668460","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516668460?lang=zh_cn&edition=full","pubTime":"2025-03-04 04:12","pubTimestamp":1741032745,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日04时12分，因塞特股票出现异动，股价急速下跌5.06%。截至发稿，该股报69.78美元/股，成交量137.436万股，换手率0.71%，振幅4.80%。因塞特股票所在的生物技术行业中，整体涨幅为0.06%。因塞特公司简介：Incyte专注于小分子药物的发现与研发。该公司首款皮肤科产品Opzelura于 2021 年获批用于治疗特应性皮炎，并于 2022 年获批用于治疗白癜风。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304041225989a5b88&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INCY","BK4532","BK4588","BK4139","BK4585","BK4550"],"gpt_icon":0},{"id":"2512115090","title":"Incyte Stock Sees Relative Strength Rating Rise To 71","url":"https://stock-news.laohu8.com/highlight/detail?id=2512115090","media":"Blockhead","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512115090?lang=zh_cn&edition=full","pubTime":"2025-02-19 05:16","pubTimestamp":1739913360,"startTime":"0","endTime":"0","summary":"Incyte shows improving price performance, earning an upgrade to its IBD Relative Strength Rating","market":"us","thumbnail":"https://www.investors.com/wp-content/uploads/2017/05/IRU5-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2017/05/IRU5-150x150.jpg"],"rights":null,"property":["rate"],"language":"en","translate_title":"Incyte股票相对强度评级升至71","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investors.com/news/incyte-stock-sees-relative-strength-rating-rise-to-71/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["INCY"],"gpt_icon":0},{"id":"2511692158","title":"因塞特2024财年实现净利润32.62百万美元，同比减少94.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511692158","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2511692158?lang=zh_cn&edition=full","pubTime":"2025-02-15 00:00","pubTimestamp":1739548830,"startTime":"0","endTime":"0","summary":"2月15日，因塞特公布财报，公告显示公司2024财年净利润为32.62百万美元，同比减少94.55%；其中营业收入为42.41亿美元，同比增加14.75%，每股基本收益为0.16美元。从资产负债表来看，因塞特总负债20.35亿美元，其中短期债务10.00百万美元，资产负债比为2.70，流动比率为1.98。机构评级：截至2025年2月15日，当前有19家机构对因塞特目标价做出预测，其中目标均价为77.42美元，其中最低目标价为52.00美元，最高目标价为100.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250215000038a2461504&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INCY"],"gpt_icon":0},{"id":"1184955330","title":"Stock Track | Incyte Plunges Nearly 10% After Hours on Q4 Earnings Miss and Disappointing Opzelura Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=1184955330","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1184955330?lang=zh_cn&edition=full","pubTime":"2025-02-11 06:58","pubTimestamp":1739228330,"startTime":"0","endTime":"0","summary":"Incyte Corporation  stock plunged around 9.93% in after-hours trading on Monday, following the release of its fourth-quarter 2024 earnings results. The biopharmaceutical company reported adjusted earnings per share  of $1.43, missing analysts' expectations of $1.56.While Incyte posted revenue of $1.18 billion for the quarter, beating estimates of $1.14 billion, the earnings miss and weaker-than-expected guidance for its key dermatology drug Opzelura appeared to weigh heavily on investor sentimen","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"由于第四季度盈利未达预期和Opzelura指引令人失望，Incyte盘后暴跌近10%","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["INCY"],"gpt_icon":0},{"id":"1157903796","title":"异动解读 | 因塞特医疗因2024年第四季度财报利润大幅失准,导致股价盘后大跌9.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=1157903796","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157903796?lang=zh_cn&edition=full","pubTime":"2025-02-11 06:58","pubTimestamp":1739228326,"startTime":"0","endTime":"0","summary":"北京时间2025年2月10日盘后,因塞特医疗股价大跌9.93%。引发这一剧烈波动的主因是该公司发布的2024年第四季度财报中,虽然销售额高于预期但关键利润指标每股收益却大幅低于分析师预期。具体来看,因塞特医疗当季每股收益为1.43美元,远低于分析师一致预期的1.56美元,差距高达8.33%。这一矛盾的现象或许意味着,公司在创收的同时未能有效控制相关成本,利润水平因此受到拖累。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["INCY"],"gpt_icon":0},{"id":"1115438012","title":"Stock Track | Incyte (INCY) Plummets 5.26% in Pre-Market Trading on Disappointing Earnings Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1115438012","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1115438012?lang=zh_cn&edition=full","pubTime":"2025-02-10 22:37","pubTimestamp":1739198264,"startTime":"0","endTime":"0","summary":"Incyte Corporation  saw its stock price plummet by 5.26% in pre-market trading on Monday, following the release of its fourth-quarter 2024 earnings results. The biotechnology company reported adjusted earnings per share  of $1.43, missing analysts' expectations of $1.56.The earnings miss appears to be the primary factor driving the stock's decline. Despite reporting revenue of $1.18 billion, which beat estimates of $1.14 billion, investors seem to have been displeased by the lower-than-expected ","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"股票追踪Incyte(INCY)因盈利结果令人失望而在盘前交易中暴跌5.26%","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["INCY"],"gpt_icon":0},{"id":"1188418672","title":"异动解读 | 因塞特医疗2024年第四季度财报暗淡,销售额虽高但每股收益大幅失准,股价盘中大跌5.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=1188418672","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188418672?lang=zh_cn&edition=full","pubTime":"2025-02-10 22:36","pubTimestamp":1739198215,"startTime":"0","endTime":"0","summary":"因塞特医疗(INCY)今日盘中出现大幅波动,股价一度大跌5.26%,引发市场广泛关注。据了解,该公司2024年第四季度业绩虽然销售额高于预期,但关键利润指标每股收益却大幅低于预期。\n具体来看,因塞特医疗当季每股收益为1.43美元,低于分析师一致预期的1.56美元,差距高达8.33%。这一利润数据不佳,可能已引发市场对公司盈利前景的担忧。\n不过,公司当季销售额11.8亿美元,则高于分析师预期的11.4亿美元,增长了3.16%。尽管销售额表现出色,但利润的大幅失准,使得市场对公司在创收的同时控制成本方面的能力存疑。业内人士分析,公司未来业绩与资金使用效率将面临挑战。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["INCY"],"gpt_icon":0},{"id":"2510863202","title":"因塞特盘中异动 股价大跌5.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510863202","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510863202?lang=zh_cn&edition=full","pubTime":"2025-02-10 22:34","pubTimestamp":1739198086,"startTime":"0","endTime":"0","summary":"北京时间2025年02月10日22时34分，因塞特股票出现异动，股价急速跳水5.29%。截至发稿，该股报70.21美元/股，成交量8.8876万股，换手率0.05%，振幅3.87%。因塞特股票所在的生物技术行业中，整体涨幅为0.35%。其相关个股中，Ocean Biomedical, Inc.、Nls Pharmaceutics Ltd.、Solid Biosciences Inc.涨幅较大，Nls Pharmaceutics Ltd.、Ocean Biomedical, Inc.、Conduit Pharmaceuticals Inc.较为活跃，换手率分别为937.28%、614.58%、259.05%，振幅较大的相关个股有Soligenix, Inc.、Tyra Biosciences, Inc.、Invivyd, Inc.，振幅分别为103.16%、100.83%、29.90%。因塞特公司简介：Incyte专注于小分子药物的发现和开发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210223446961e00d0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4532","BK4588","BK4139","BK4585","INCY","BK4550"],"gpt_icon":0},{"id":"2510852385","title":"Incyte Corp Reports Q4 2024 Revenue of $1.2 Billion, Beating Estimates; EPS of $1.04 Misses Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2510852385","media":"GuruFocus","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510852385?lang=zh_cn&edition=full","pubTime":"2025-02-10 20:37","pubTimestamp":1739191048,"startTime":"0","endTime":"0","summary":"On February 10, 2025, Incyte Corp (INCY, Financial) released its 8-K filing detailing the financial results for the fourth quarter and full year of 2024. The company reported total revenues of $1.2 bi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"Incyte Corp报告2024年第四季度营收为12亿美元，超出预期；每股收益1.04美元未达预期","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gurufocus.com/news/2688800/incyte-corp-reports-q4-2024-revenue-of-12-billion-beating-estimates-eps-of-104-misses-expectations","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gurufocus_highlight","symbols":["INCY"],"gpt_icon":0},{"id":"1185456279","title":"Incyte公司预测2025年Jakafi收入为29.25亿至29.75亿美元，Opzelura销售额为6.30亿至6.70亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1185456279","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1185456279?lang=zh_cn&edition=full","pubTime":"2025-02-10 20:17","pubTimestamp":1739189878,"startTime":"0","endTime":"0","summary":"Incyte公司预测2025年Jakafi收入为29.25亿至29.75亿美元，Opzelura销售额为6.30亿至6.70亿美元以上内容来自Benzinga Earnings专栏，原文如下：Incyte Forecasts 2025 Jakafi Revenue Of $2.925B-$2.975B And Opzelura Sales Of $630M-$670M","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INCY"],"gpt_icon":0},{"id":"1141658251","title":"Incyte 2024年第四季度调整后每股收益为$1.43，低于预期的$1.56，销售额$11.8亿高于预期的$11.4亿","url":"https://stock-news.laohu8.com/highlight/detail?id=1141658251","media":"财报速递","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1141658251?lang=zh_cn&edition=full","pubTime":"2025-02-10 20:02","pubTimestamp":1739188979,"startTime":"0","endTime":"0","summary":"Incyte  报告其季度每股收益为$1.43，低于分析师一致预期的$1.56，差距为8.33%。公司报告其季度销售额为$11.8亿，高于分析师一致预期的$11.4亿，超出了3.16%。这一数字相比去年同期的$10.1亿增加了16.39%。以上内容来自Benzinga Earnings专栏，原文如下：Incyte  reported quarterly earnings of $1.43 per share which missed the analyst consensus estimate of $1.56 by 8.33 percent. This is a 34.91 percent increase over earnings of $1.06 per share from the same period last year.  The company reported quarterly sales of $1.18 billion which beat the analyst consensus estimate of $1.14 billion by 3.16 perc","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Incyte 2024年第四季度调整后每股收益为$1.43，低于预期的$1.56，销售额$11.8亿高于预期的$11.4亿","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INCY"],"gpt_icon":0},{"id":"2510885646","title":"Incyte Forecasts 2025 Jakafi Revenue Of $2.925B-$2.975B And Opzelura Sales Of $630M-$670M","url":"https://stock-news.laohu8.com/highlight/detail?id=2510885646","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510885646?lang=zh_cn&edition=full","pubTime":"2025-02-10 20:02","pubTimestamp":1739188975,"startTime":"0","endTime":"0","summary":"Incyte Forecasts 2025 Jakafi Revenue Of $2.925B-$2.975B And Opzelura Sales Of $630M-$670M","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"Incyte预测2025年Jakafi收入为$29.25 B-$29.75 B，Opzelura销售额为$6.3亿-$6.7亿","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/general/biotech/25/02/43588488/incyte-forecasts-2025-jakafi-revenue-of-2-925b-2-975b-and-opzelura-sales-of-630m-670m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INCY"],"gpt_icon":0},{"id":"2510480855","title":"Incyte Q4 2024 Adj EPS $1.43 Misses $1.56 Estimate, Sales $1.18B Beat $1.14B Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2510480855","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510480855?lang=zh_cn&edition=full","pubTime":"2025-02-10 20:01","pubTimestamp":1739188891,"startTime":"0","endTime":"0","summary":"Incyte (NASDAQ:INCY) reported quarterly earnings of $1.43 per share which missed the analyst consensus estimate of $1.56 by 8.33 percent. This is a 34.91 percent increase over earnings of $1.06 per share from the same","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"Incyte 2024年第四季度调整后EPS$1.43低于$1.56预期，销售额$1.18 B超出$1.14 B预期","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/02/43588435/incyte-q4-2024-adj-eps-1-43-misses-1-56-estimate-sales-1-18b-beat-1-14b-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Incyte Q4 2024 Adj EPS $1.43 Misses $1.56 Estimate, Sales $1.18B Beat $1.14B Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INCY"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.incyte.com","stockEarnings":[{"period":"1week","weight":0.0175},{"period":"1month","weight":-0.1129},{"period":"3month","weight":-0.1036},{"period":"6month","weight":-0.0765},{"period":"1year","weight":0.1164},{"period":"ytd","weight":-0.0976}],"compareEarnings":[{"period":"1week","weight":-0.0072},{"period":"1month","weight":-0.033},{"period":"3month","weight":-0.0344},{"period":"6month","weight":-0.0148},{"period":"1year","weight":0.088},{"period":"ytd","weight":-0.0368}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"因塞特医疗公司于1991年在特拉华州注册成立。该公司是一家全球生物制药公司，致力于专有疗法的发现、开发和商业化。该公司专注于两个治疗领域，这两个领域由其获批药物的适应症和其临床候选药物正在开发的疾病定义。一个治疗领域是血液学/肿瘤学，包括骨髓增生性肿瘤(MPN)、移植物抗宿主病(GVHD)、实体瘤和血液系统恶性肿瘤。另一个治疗领域是炎症和自身免疫(IAI)，包括其皮肤病学商业特许经营权。该公司还有权获得其发现并授权给第三方的分子的里程碑和特许权使用费。","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":0.086406},{"month":2,"riseRate":0.3125,"avgChangeRate":-0.001863},{"month":3,"riseRate":0.4375,"avgChangeRate":-0.038633},{"month":4,"riseRate":0.46875,"avgChangeRate":-0.011368},{"month":5,"riseRate":0.612903,"avgChangeRate":0.062613},{"month":6,"riseRate":0.580645,"avgChangeRate":0.023436},{"month":7,"riseRate":0.516129,"avgChangeRate":0.013155},{"month":8,"riseRate":0.516129,"avgChangeRate":0.015671},{"month":9,"riseRate":0.387097,"avgChangeRate":-0.020225},{"month":10,"riseRate":0.516129,"avgChangeRate":0.02439},{"month":11,"riseRate":0.580645,"avgChangeRate":0.059578},{"month":12,"riseRate":0.612903,"avgChangeRate":0.098493}],"exchange":"NASDAQ","name":"因塞特医疗","nameEN":"Incyte"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"因塞特医疗(INCY)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供因塞特医疗(INCY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"因塞特医疗,INCY,因塞特医疗股票,因塞特医疗股票老虎,因塞特医疗股票老虎国际,因塞特医疗行情,因塞特医疗股票行情,因塞特医疗股价,因塞特医疗股市,因塞特医疗股票价格,因塞特医疗股票交易,因塞特医疗股票购买,因塞特医疗股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"因塞特医疗(INCY)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供因塞特医疗(INCY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}